The Company expects to have ibogaine manufactured and in use for research by Q4. VANCOUVER, BC, March 3, 2021 /CNW/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ( “MINDCURE” or the “Company”) a leader in advanced proprietary technology for psychedelic drug discovery, is pleased to announce that it has begun the first stage of manufacturing pharmaceutical grade ibogaine to be used…


Previous articleAwakn Announces Exclusive License Deal with the University of Exeter to Commercialise the ‘Ketamine in the Reduction of Alcoholic Relapse’ (KARE) Intervention Validated in a Phase II Clinical Trial
Next articleBetterLife Engages Eurofins CDMO for Next Generation Psychedelic TD-0148A Manufacturing